Summary of Conference Call on Biopharmaceutical Company Company and Industry Overview - **Company**: Biopharmaceutical Company (生物股份) - **Industry**: Animal Vaccines, specifically focusing on African Swine Fever (ASF) vaccines Key Points and Arguments Clinical Progress and Results - The clinical progress of the ASF subunit vaccine is on track, achieving a 100% protection rate in the first round of challenge tests, exceeding the Ministry's standard of 80% [2][4] - A second challenge test is scheduled for April 12, 2026, with results expected in early May 2026. If successful, the company could receive a temporary production license by Q3 2026 [4][11] Competitive Advantages - Biopharmaceutical Company is the only GCP (Good Clinical Practice) contractor for the ASF vaccine, providing a competitive edge with a validated process and a potential market exclusivity of 1 to 1.5 years [2][6] - The company has invested nearly 600 million yuan in the project, including 200 million yuan for a P3 laboratory and another 200 million yuan for the production line, establishing high entry barriers in the industry [2][7] Production Capacity and Pricing - The company has established a production line capable of producing 300 million doses annually, with an expected price of around 25 yuan per dose and a target market penetration of 20%-30% [2][5] Technical Coverage and Efficacy - The subunit vaccine is effective against both type I and type II ASF strains, with a reserve of mRNA vaccine technology soon to be submitted for approval [2][8] - The challenge dose for the vaccine was set at 8,000 HAD, and the vaccine has shown effectiveness against the majority of circulating strains [8] Market Dynamics and Future Outlook - The ASF vaccine market may face competition in the future, but any new entrants are expected to emerge in two to three years. The market will likely be shared among a few companies, with a stable demand from China's 700 million pigs [9][10] - Even if prices decrease due to competition, the company anticipates maintaining profit margins through economies of scale as production volumes increase [10] Customer Engagement and Market Acceptance - The company is engaging with both large-scale farms and smallholders, with notable interest from major players like Zhengda Group. The involvement of significant shareholders indicates strong market demand for the vaccine [10] Upcoming Milestones - Key upcoming milestones include the second challenge test on March 12, 2026, with results expected in May 2026. Following successful results, the company anticipates receiving a temporary production license by Q3 2026 [11]